Sun Pharma Halol facility faces US FDA import alert

Halol plant in Gujarat has been placed under “Official Action Indicated” (OAI) status by the US FDA after an inspection in June 2025, keeping the facility under import alert and halting shipments to the US, except for products exempted due to shortages. The action highlights non-compliance with cGMP norms, though the company has reiterated its commitment to corrective measures. Recently, BofA Securities downgraded the stock to underperform, trimming the price target to ₹1,570 amid earnings risk. For the June quarter, India’s largest drugmaker reported consolidated revenue of ₹13,821 crore, EBITDA up 19.2% YoY to ₹4,302 crore with margins at 31%, while net profit dropped to ₹3,172.7 crore due to a one-time charge of ₹818 crore. The regulatory setback adds pressure at a time when valuations are already under scrutiny. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.